Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)

Clinical Endocrinology

Volumn 52, Issue 4, 2000, Pages 487-492

  Atiomo, William U ^a,d   Fox, Robert ^c   Condon, John E ^a   Shaw, Stephen ^b   Friend, J ^a   Prentice, Archibald G ^a   Wilkin, Terence J ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c MUSGROVE PARK HOSPITAL   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; CHOLESTEROL; FIBRINOGEN; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE DETERMINATION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0002443834     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.00946.x     Document Type: Article

References (17)

1. Adams, J., Polson, D., Abdulwahid, N., Morris, D.V., Franks, S., Mason, H.D., Tucker, M. & Price, J. (1985) Multifolliular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet, ii, 1375-1378.
2. Anderson, P., Seljeflot, I., Abdelnoor, M., Arnesen, H., Dale, P.O., Lovik, A. & Birkeland, K. (1995) Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism, 44, 611-616.
3. Atiomo, W.U., Bates, S.A., Condon, J.E., Shaw, S., West, J.H. & Prentice, A.G. (1998) The plasminogen activator system in women with polycystic ovary syndrome. Fertility and Sterility, 69, 236-241.
4. Dahlgren, E., Jansen, O.P., Johansson, S., Lapidus, L., Lindstedt, G. and Tengborn, L. (1994) Haemostatic and metabolic variables in women with the polycystic ovary syndrome. Fertility and Sterility, 61, 455-459.
5. Francis, C. & Marder, V. (1995) Mechanisms of fibrinolysis. In: Williams Haematology (eds. E. Beutler, M. Licthman, B. Coller and T. Kipps.) pp. 1252-1260. McGraw Hill, New York.
6. Franks, S. (1995) Polycystic Ovary Syndrome. New England Journal of Medicine, 333, 853-861.
7. Juhan-Vague, I., Alessi, M.C., Raccah, D., Ailluad, M.F., Billery, M., Ansaldi, J., Philip-Joet, C. & Vague, P. (1992) Daytime fluctuations of plasminogen activator inhibitor-1 (PAI-1) in populations with high PAI-1 levels. Thrombosis and Haemostasis., 67, 76-82.
8. Nestler, J.E. & Jakubowicz, D.J. (1996) Decreases in ovarian cytochrome P450c17alpha activity and serum free testosterone levels after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine, 335, 617-623.
9. Peng, X.-R., Aaron, J.W. & Hsueh and Tor, N.Y. (1993) Transient and cell specific expression of tissue type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during Gonadotrophin-induced ovulation. European Journal of Biochemistry, 214, 147-145.
10. Piquette, G., Simon, C., Danaouri, I.E., Frances, A. & Polan, L.A. (1994) Gene regulation of interleukin-1 B, interleukin-1 receptor type 1, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells. Fertility and Sterility, 62, 760-770.
11. Reaven, G.M. (1994) Syndrome X: 6 years later. Journal of Internal Medicine, 236 (Suppl.), 13-22.
12. Robinson, S., Kiddy, D., Gelding, S.V., Willis, D., Nithyinanthan, R., Bush, A., Johnston, D.G. & Franks, S. (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology, 39, 351-355.
13. Rudenski, A.S., Matthews, D.R., Levy, J.C. & Turner, R.C. (1991) Understanding 'insulin resistance': Both glucose resistance and insulin resistance are required to model human diabetes. Metabolism, 40, 908-917.
14. Sampson, M., Kong, C., Patel, A., Unwin, R. & Jacobs, H.S. (1996) Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology, 45, 623-629.
15. Sappino, A.P., Huarte, J., Belin, D. & Vassali, J.D. (1989) Plasminogen activators in tissue remodelling and Invasion: m RNA Localisation in mouse ovaries and implanting embryos. The Journal of Cell Biology, 109, 2471-2479.
16. Tsafriri, A., Bicsak, T.A., Cajander, S.B., Ny, T. & Hsuesh, A.J.W. (1989) Suppression of ovulation rate by antibodies to tissue type plasminogen activator and alpha2 antiplasmin. Endocrinology, 124, 415-421.
17. Velazquez, E.M., Mendoza, S.G., wang, P. & Glueck, C.J. (1997) Metformin therapy is associated with a decrease in plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism: Clinical and Experimental., 46, 454-457.